My thoughts are that since OPT302 is intended to be used as a combination with a VEGF-A treatment, the dosing interval wouldn't need to be more frequent than the VEGF-A agent, whatever it may be. And if the combination has greater efficacy it's even possible it may extend the interval between treatments. At least, that's the way I have been thinking. So extended duration might result from combination of OPT302 with say Lucentis or Eyelea.
What matters most? Acuity or Duration? What if Opthea was wrong?, page-10
-
- There are more pages in this discussion • 7 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add OPT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
0.005(1.37%) |
Mkt cap ! $403.8M | |||
| Open | High | Low | Value | Volume |
| 36.5¢ | 38.5¢ | 36.0¢ | $606.6K | 1.610M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 75584 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 33006 | 1 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| OPT (ASX) Chart |